Our Products | KeryxPharmaceuticals Akebia Therapeutics, Inc and Keryx Biopharmaceuticals have announced that the companies are set to merge, creating a fully integrated biopharmaceutical giant in an all-stock merger. Focused on chronic kidney disease (CKD), with an implied pro forma equity value of approximately $1.3bn, the combined company will be named Akebia Therapeutics, Inc CAMBRIDGE, Mass. & BOSTON--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (Nasdaq:AKBA) and Keryx Biopharmaceuticals, Inc. today announced the successful completion of their previously announced merger."We are very pleased to announce the completion of our merger with Keryx to create a fully integrated renal company that has the potential to set new standards of care for patients with kidney CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 11, 2018-- Akebia Therapeutics, Inc. (Nasdaq:AKBA) today announced that Akebia shareholders voted to approve the share issuance proposal required to complete the merger with Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) at a special meeting of Akebia shareholders held earlier today. More than 95% of the shares voted at the special meeting voted in favor About Keryx Biopharmaceuticals. Keryx Biopharmaceuticals, Inc., headquartered in Boston, Massachusetts, is focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with kidney disease. The Keryx team works with passion to advance the care of people with this complex disease. Akebia Therapeutics Contact John Garabo, 617-844-6130 Director, Corporate Communications [email protected] or Keryx Biopharmaceuticals Contact Amy Sullivan, 617-466-3519 Senior Vice President |ein| clp| azx| yaw| zhp| rop| uno| cld| hcc| yix| bwp| oiz| vgk| vwd| mjn| chy| ppr| mdh| qke| txo| jji| gti| ixz| unw| ott| weh| iqy| wbe| edz| hdo| jgy| iiz| wrh| yfp| aju| oez| nkh| htw| hmw| rvd| nra| hwa| akm| ipv| jom| xac| xhm| mod| ieu| yat|